A 15-amino-acid sequence derived from a partial sequence of human gastric juice protein BPC. No single receptor has been validated. The most cited proposed mechanisms are upregulation of VEGFR2 signalling and consequent angiogenesis, interaction with the nitric oxide system, and modulation of growth factor expression at injury sites. Mechanistic understanding remains genuinely incomplete — this is a peptide whose popularity substantially exceeds its mechanistic characterisation.
The preclinical literature is large: rodent models report accelerated healing of tendon, ligament, muscle, bone, and gastrointestinal mucosa, with much of it originating from a small number of affiliated research groups. Adequate, well-controlled human trials are absent. A related molecule (PL 14736) entered early clinical study for inflammatory bowel disease and did not proceed to approval. The gap between rodent findings and demonstrated human benefit is the central fact about BPC-157.
Not FDA-approved. No USP monograph. Placed in 503A Category 2 in September 2023 — substances that may present significant safety risks — barring compounding. Removed from Category 2 in April 2026 after the nomination was withdrawn, but not added to Category 1, leaving it neither expressly permitted nor prohibited. FDA's Pharmacy Compounding Advisory Committee was scheduled to consider BPC-157 (free base) and BPC-157 acetate for the 503A Bulks List at its July 23–24, 2026 meeting. This status is actively moving; verify before relying on anything here. Prohibited in sport (WADA S0).
Rodent toxicity studies report wide margins, and that is genuinely the extent of it. There is no long-term human safety data. Because a principal proposed mechanism is angiogenesis, the theoretical concern raised repeatedly by regulators and clinicians is that a pro-angiogenic agent may act on tissue you did not intend to grow. That concern is unresolved, not disproven — and it is why the substance drew Category 2 designation.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.